Bedrijf laden
Just reported
Q3 2026 results
From AbbVie's results release of 30 oktober 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 17,4B
+10% y/y
+2,4% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 2,37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 6,27B
+229% y/y
-2,6% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$ 1,35TA+
JNJJohnson & JohnsonUS$ 682,6BA+
MRKMerck & Co., Inc.US$ 362,2BA
NVSNovartis AGUS$ 305,8BA
AMGNAmgen Inc.US$ 252,6BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Hoe het geld verdient
- Sales of medicines and therapies100%
De omzetaandelen zijn schattingen voor fiscal year 2025, high confidence, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt6
Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.
Nog 3 tonen
Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.
Wie het koopt5
- Wholesalers and distributors buy medicines for resale to pharmacies, hospitals and other healthcare providers.
- Government agencies and public health programs buy medicines or set coverage and reimbursement terms.
- Health insurers and pharmacy benefit managers influence which medicines patients can access and the prices or rebates paid.
Nog 2 tonen
- Hospitals, health facilities, specialty pharmacies and independent pharmacies buy medicines for use or dispensing to patients.
- Physicians and other licensed healthcare providers prescribe AbbVie's prescription medicines and can buy some aesthetic products and devices directly.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1AbbVie relies on large wholesale distributors to move its medicines, especially in the United States.
- 2Some medicines or manufacturing components depend on a limited number of suppliers, and in some cases a single supply source.
- 3Revenue depends on patents and regulatory exclusivity; Humira already faces biosimilar competition.
- 4Pricing and patient access depend partly on government reimbursement rules, insurers and pharmacy benefit managers.
- 5The business depends on discovering, testing and obtaining regulatory approval for new medicines, including products developed with collaborators.
Wat er mis kan gaan
- 1Patent expirations and biosimilar or generic competition can reduce sales. Humira's sales continued to fall amid biosimilar competition in the six months ended June 30, 2026.
- 2Government price controls, reimbursement limits and pressure from insurers and pharmacy benefit managers can reduce the prices AbbVie receives for its medicines.
- 3Research and development may not produce medicines that pass clinical trials and regulatory review or attract enough use after approval, leaving gaps as existing products lose exclusivity.
Over AbbVie Inc.
AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.
- Hoofdkantoor
- North Chicago, Illinois, United States
- Opgericht in
- 2012 (incorporated; began independent public trading in 2013)
- Medewerkers
- Approximately 57,000 (December 31, 2025, high confidence)
- Genoteerd aan
- New York Stock Exchange
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van AbbVie Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.